The global artificial intelligence (AI) in drug discovery market size is expected to reach US$4.05 billion by 2028 according to a new study by Polaris Market Research. The report “Artificial Intelligence in Drug Discovery Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases, Infectious Disease, Others); By Application; By Regions; Segment Forecast, 2021 – 2028” gives insight into current market dynamics and provides analysis on future market growth.
Based on therapeutic areas, the global AI in drug discovery market is segmented into oncology, neurodegenerative diseases, cardiovascular disease, metabolic diseases, infectious diseases, and more. In 2020, the oncology segment accounted for the largest revenue share. AI plays an important role in the pre-diagnosis of cancer.
AI platforms are designed to ascertain genetic mutations, helping oncologists in designing effective treatment plans. In this line, a Switzerland-based company, Sophia Genetics developed an AI platform that helps to identify tumours by detecting genetic variations and devising personalised cancer treatment plans.
However, the infectious disease segment of AI in the drug discovery industry is projected to witness a lucrative growth rate over the study period. The increasing adoption of AI platforms in infectious diseases to identify key infection patterns. A positive scenario for the segment is also illustrated by key partnerships and collaborations in the market AI in drug discovery.